Abstract
Lung cancer remains a global health problem with a high mortality rate. CpG island methylation is a common aberration frequently associated with gene silencing in multiple tumor types, emerging as a highly promising biomarker. The transmembrane protein with a single EGF-like and two follistatin domains (TMEFF2) is epigenetically silenced in numerous tumor types, suggesting a potential role as a potential tumor suppressor. However, the role of TMEFF2 in lung cancer remains to be fully elucidated. We explored the methylation status of TMEFF2 gene in 139 patients with non-small cell lung cancer (NSCLC) and the feasibility of detecting circulating methylated DNA as a screening tool for NSCLC using methylation-specific PCR in 316 patients and 50 age-matched health controls. TMEFF2 methylation in tumor tissues was found in 73 of the 139 NSCLCs (52.5%) and was related to gene expression. The frequency of TMEFF2 methylation was higher in females and never-smokers than in males and smokers with borderline significance (65.8% vs 47.8%, p = 0.06; 65.7% vs 48.1%, p = 0.07). Notably, in adenocarcinomas, TMEFF2 methylation was significantly more frequent in tumors without EGFR mutation than those with EGFR mutation (adjusted odds ratio = 7.13, 95% confidence interval = 2.05-24.83, P = 0.002). Furthermore, TMEFF2 methylation was exclusively detected in the serum of NSCLC patients at a frequency of 9.2% (29/316). These findings suggest that methylation-associated down-regulation of TMEFF2 gene may be involved in lung tumorigenesis and TMEFF2 methylation can serve as a specific blood-based biomarker for NSCLC.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ali, N., and Knaüper, V. (2007). Phorbol ester-induced shedding of the prostate cancer marker transmembrane protein with epidermal growth factor and two follistatin motifs 2 is mediated by the disintegrin and metalloproteinase-17. J. Biol. Chem. 282, 37378–37388.
Anglim, P.P., Alonzo, T.A., and Laird-Offringa, I.A. (2008). DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update. Mol. Cancer 7, 81–94.
Baylin, S.B., and Ohm, J.E. (2006). Epigenetic gene silencing in cancer — an early oncogenic pathway addiction? Nat. Rev. Cancer 6, 107–116.
Beder, L.B., Gunduz, M., Ouchida, M., Fukushima, K., Gunduz, E., Ito, S., Sakai, A., Nagai, N., Nishizaki, K., and Shimizu, K. (2003). Genome-wide analyses on loss of heterozygosity in head and neck squamous cell carcinomas. Lab. Invest. 83, 99–105.
Belinsky, S.A. (2004). Gene-promoter hypermethylation as a biomarker in lung cancer. Nat. Rev. Cancer 4, 1–11.
Belinsky, S.A., Palmisano, W.A., Gilliland, E.D., Crooks, L.A., Divine, K.K., Winters, S.A., Grimes, M.J., Harms, H.J., Tellez, C.S., Smith, T.M., et al. (2002). Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res. 62, 2370–2377.
Bremnes, R.M., Sirera, R., and Camps, C. (2005). Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up? Lung Cancer 49, 1–12.
Chung, J.H., Lee, H.J., Kim, B.H., Cho, N.Y., and Kang, G.H. (2011). DNA methylation profile during multistage progression of pulmonary adenocarcinomas. Virchows Arch. 459, 201–211.
Elahi, A., Zhang, L., Yeatman, T.J., Gery, S., Sebti, S., and Shibata, D. (2008). HPP1-mediated tumor suppression requires activation of STAT1 pathways. Int. J. Cancer 122, 1567–1572.
Field, J.K., Liloglou, T., Warrak, S., Burger, M., Becker, E., Berlin, K., Nimmrich, I., and Maier, S. (2005). Methylation discriminators in NSCLC identified by a microarray based approach. Int. J. Oncol. 27, 105–111.
Gery, S., Sawyers, C.L., Agus, D.B., Said, J.W., and Koeffler, H.P. (2002). TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cells. Oncogene 21, 4739–4746.
Glynne-Jones, E., Harper, M.E., Seery, L.T., James, R., Anglin, I., Morgan, H.E., Taylor, K.M., Gee, J.M., and Nicholson, R.I. (2001). TENB2, a proteoglycan identified in prostate cancer that is associated with disease progression and androgen independence. Int. J. Cancer 94, 178–184.
Guo, M., House, M.G., Hooker, C., Han, Y., Heath, E., Gabrielson, E., Yang, S.C., Baylin, S.B., Herman, J.G., and Brock, M.V. (2004). Promoter hypermethylation of resected bronchial margins: a field defect of changes? Clin. Cancer Res. 10, 5131–5136.
Heller, G., Zielinski, C.C., and Zochbauer-Muller, S. (2010). Lung cancer: from single-gene methylation to methylome profiling. Cancer Metastasis Rev. 29, 95–107.
Huang, Z.H., Li, L.H., Yang, F., and Wang, J.F. (2007). Detection of aberrant methylation in fecal DNA as a molecular screening tool for colorectal cancer and precancerous lesions. World J. Gastroenterol. 13, 950–954.
Ivanauskas, A., Hoffmann, J., Jonaitis, L.V., Markelis, R., Juozaityte, E., Kupcinskas, L., Lofton-Day, C., Rocken, C., and Malfertheiner, P. (2008). Distinct TPEF/HPP1 gene methylation patterns in gastric cancer indicate a field effect in gastric carcinogenesis. Dig. Liver Dis. 40, 920–926.
Jahr, S., Hentze, H., Englisch, S., Hardt, D., Fackelmayer, F.O., Hesch, R.D., and Knippers, R. (2001). DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 61, 1659–1665.
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., and Thun, M.J. (2008). Cancer statistics, 2008. CA Cancer J. Clin. 58, 71–96.
Jones, P.A., and Baylin, S.B. (2002). The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3, 415–428.
Lee, S.M., Na, Y.K., Hong, H.S., Jang, E.J., Yoon, G.S., Park, J.Y., and Kim, D.S. (2011). Hypomethylation of the thymosin 10 gene is not associated with its overexpression in non-small cell lung cancer. Mol. Cells 32, 343–348.
Liang, G., Robertson, K.D., Talmadge, C., Sumegi, J., and Jones, P.A. (2000). The gene for a novel transmembrane protein containing epidermal growth factor and follistatin domains is frequently hypermethylated in human tumor cells. Cancer Res. 60, 4907–4912.
Lin, K., Taylor, J.R., Wu, T.D., Gutierrez, J., Elliott, J.M., Vernes, J.M., Koeppen, H., Phillips, H.S., de Sauvage, F.J., and Meng, Y.G. (2011). TMEFF2 is a PDGF-AA binding protein with methylation-associated gene silencing in multiple cancer types including glioma. PLoS One 6, e18608.
Lofton-Day, C., Model, F., DeVos, T., Tetzner, R., Distler, J., Schuster, M., Song, X., Lesche, R., Liebenberg, V., Ebert, M., et al. (2008). DNA methylation biomarkers for blood-based colorectal cancer screening. Clin. Chem. 54, 414–423.
Minna, J.D., Roth, J.A., and Gazdar, A.F. (2002). Focus on lung cancer. Cancer Cell 1, 49–52.
Otsuka, T., Kohno, T., Mori, M., Noguchi, M., Hirohashi, S., and Yokota, J. (1996). Deletion mapping of chromosome 2 in human lung carcinoma. Genes Chromosomes Cancer 16, 113–119.
Russo, A.L., Thiagalingam, A., Pan, H., Califano, J., Cheng, K., Ponte, J.F., Chinnapan, D., Nemani, P., Sidransky, D., and Thiagalingam, S. (2005). Differential DNA hypermethylation of critical genes mediates the stage-specific tobacco smoke-induced neoplastic progress of lung cancer. Clin. Cancer Res. 11, 2466–2470.
Sabbioni, S., Miotto, E., Veronese, A., Sattin, E., Gramantieri, L., Bolondi, L., Calin, G.A., Gafà, R., Lanza, G., Carli, G., et al. (2003). Multigene methylation analysis of gastrointestinal tumors: TPEF emerges as a frequent tumor-specific aberrantly methylated marker that can be detected in peripheral blood. Mol. Diagn. 7, 201–207.
Selamat, S.A., Galler, J.S., Joshi, A.D., Fyfe, M.N., Campan, M., Siegmund, K.D., Kerr, K.M., and Laird-Offringa, I.A. (2011). DNA methylation changes in atypical adenomatous hyperplasia, adenocarcinoma in situ, and lung adenocarcinoma. PLoS One 6, e21443.
Shigematsu, H., and Gazdar, A.F. (2006). Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int. J. Cancer 118, 257–262.
Suzuki, M., Shigematsu, H., Shames, D.S., Sunaga, N., Takahashi, T., Shivapurkar, N., Lizasa, T., Frenkel, E.P., Minna, J.D, Fujisawa, T., et al. (2005). DNA methylation-associated inactivation of TGFβ-related genes DRM/Gremlin, RUNX3, and HPP1 in human cancers. Oncogene 93, 1029–1037.
Takita, J., Yang, H.W., Chen, Y.Y., Hanada, R., Yamamoto, K., Teitz, T., Kidd, V., and Hayashi, Y. (2001). Allelic imbalance on chromosome 2q and alterations of the caspase 8 gene in neuroblastoma. Oncogene 20, 4424–4432.
Toyooka, S., Maruyama, R., Toyooka, K.O., McLerran, D., Feng, Z., Fukuyama, Y., Virmani, A.K., Zochbauer-Muller, S., Tsukuda, K., Sugio, K., et al. (2003). Smoke exposure, histologic type and geography-related differences in the methylation profiles of nonsmall cell lung cancer. Int. J. Cancer 103, 153–160.
Young, J., Biden, K.G., Simms, I.A., Huggard, P., Karamatic, R., Eyre, H.J., Sutherland, G.R., Herath, N., Barker, M., Anderson, G.J., et al. (2001). HPP1: a transmembrane protein-encoding gene commonly methylated in colorectal polyps and cancers. Proc. Natl. Acad. Sci. USA 98, 265–270.
Author information
Authors and Affiliations
Corresponding authors
About this article
Cite this article
Lee, S.M., Park, J.Y. & Kim, D.S. Methylation of TMEFF2 gene in tissue and serum DNA from patients with non-small cell lung cancer. Mol Cells 34, 171–176 (2012). https://doi.org/10.1007/s10059-012-0083-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10059-012-0083-5